Recombinant human interferon alpha-2b (Hualida Biotech)

重组人干扰素α2b注射液（天津未名生物）

Report date: 2024/12/11 14:07:41

Base Information

Drug NameRecombinant human interferon alpha-2b (Hualida Biotech)
Drug Alias Name安福隆
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsNeoplasmsVirus Diseases
Global Approved IndicationsNeoplasmsVirus Diseases
Approved Indications in ChinaNeoplasmsVirus Diseases
Original Approved Country/TerritoryMainland China
Original Approved Date1997/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinobioway Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTianjin Sinobioway Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasmsVirus Diseases
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A